–News Direct–

Cure Alzheimers Fund, a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimers disease, has announced the recipients of the inaugural Jeffrey L. Morby Prize. Senior author David M. Holtzman, M.D., and first author Xiaoying Chen, Ph.D., both of Washington University School of Medicine in St. Louis, were selected by their peers for their paper Microglia-Mediated T Cell Infiltration Drives Neurodegeneration in Tauopathy, published in Nature in March 2023.

The Morby Prize is named in honor of the late Co-Founder of Cure Alzheimers Fund, Jeffrey L. Morby, who inspired the nonprofits mission 20 years ago to fund research as a path to ending Alzheimers disease. Mr. Morby passed away in September 2023.

Established this year, the Morby prize will be awarded annually to the senior and first authors of a recent scientific publication that transforms the fundamental understanding of Alzheimers disease and opens new paths to translate scientific results into effective ways to prevent, diagnose or treat the disease. This years award included $200,000 for the senior authors lab for Alzheimers disease-related research.

Recognizing researchers for a paper selected by peer scientists for breakthrough thinking and benefit to the Alzheimers community befits Jeffs wonderful legacy of empowering scientists to achieve rigorous and innovative science, said Meg Smith, CEO of Cure Alzheimers Fund. The many extraordinary CureAlz-funded projects that resulted in published papers in 2022 and 2023 made the competition for this award fierce, and the endorsement of this paper by their peers speaks to the importance of the work of Drs. Holtzman and Chen and their co-authors. Their compelling data challenge the old paradigm that the adaptive immune system has little role in neurodegenerative disease, and by doing so opens new avenues to explore for effective intervention in Alzheimers disease.

Added Dr. Holtzman: Both Xiaoying Chen and I and our many outstanding co-authors are very honored to receive recognition for the work in our recently published paper. There remain many unanswered questions about the exact role of the adaptive immune response in the pathogenesis of Alzheimers disease. I think this work along with work from others in the field is pushing us to understand how important adaptive immunity is in Alzheimers disease and other tauopathies, as well as whether targeting it will ultimately be therapeutically beneficial to people.

About The Holtzman Lab

David M. Holtzman, Ph.D. is a neurologist and neuroscientist who has focused much of his efforts over the past 30 years on trying to better understand mechanisms underlying neurodegeneration, particularly as they are relevant to Alzheimers disease (AD). Xiaoying Chen, Ph.D., was a postdoc research associate in the Holtzman Lab and is first author of the winning paper. The Holtzman Lab at Washington University School of Medicine in St. Louis has published extensively on the neurobiology of apoE as it relates to the innate immune system and how apoE and other factors such as neuronal activity and sleep influence A and tau metabolism, their accumulation, and their effects in the brain. For more information, visit

About Cure Alzheimer's Fund

Cure Alzheimers Fund is a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimers disease. Since its founding in 2004, Cure Alzheimers Fund has provided 848 grants to more than 300 of the worlds leading researchers and contributed $202 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimers disease. Cure Alzheimers Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. Our Board of Directors, Trustees and a core group of other donors direct their donations to CureAlz overhead expenses so that 100% of general donations go to our research program. For more information, visit To learn about the impact of Alzheimers on women and women working toward a cure, visit

Contact Details

Barbara Chambers

+1 978-417-9890

Company Website

View source version on

Alzheimers Disease Research Foundation

comtex tracking


Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Brite View Research journalist was involved in the writing and production of this article.